C

Cutia Therapeutics
HKEX:2487

Watchlist Manager
Cutia Therapeutics
HKEX:2487
Watchlist
Price: 6.83 HKD -2.01% Market Closed
Market Cap: 2.2B HKD
Have any thoughts about
Cutia Therapeutics?
Write Note

Intrinsic Value

The intrinsic value of one Cutia Therapeutics stock under the Base Case scenario is 11.5 HKD. Compared to the current market price of 6.83 HKD, Cutia Therapeutics is Undervalued by 41%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

Intrinsic Value
11.5 HKD
Undervaluation 41%
Intrinsic Value
Price
C
Base Case Scenario

Valuation History
Cutia Therapeutics

Intrinsic Value History
Dive into the past to invest in the future

Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start now and learn if your stock is truly undervalued or overvalued!

Start Valuation
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Valuation History Unavailable

Historical valuation for Cutia Therapeutics cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
How do you feel about Cutia Therapeutics?
Bearish
Neutral
Bullish

Fundamental Analysis

6.83 HKD
-2.01%
-2.01%
Benchmark
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Cutia Therapeutics
CN
Biotechnology
Market Cap
2.1B HKD
IPO
Jun 12, 2023
Employees
175
China
Market Cap
2.1B HKD
Industry
Biotechnology
IPO
Jun 12, 2023
Company Overview
Loading...
Economic Moat
Loading...
Management
Loading...
Contacts
Loading...
AI Assistant
AI Assistant
Ask me anything about Cutia Therapeutics

Provide an overview of the primary business activities
of Cutia Therapeutics.

What unique competitive advantages
does Cutia Therapeutics hold over its rivals?

What risks and challenges
does Cutia Therapeutics face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Cutia Therapeutics.

Provide P/S
for Cutia Therapeutics.

Provide P/E
for Cutia Therapeutics.

Provide P/OCF
for Cutia Therapeutics.

Provide P/FCFE
for Cutia Therapeutics.

Provide P/B
for Cutia Therapeutics.

Provide EV/S
for Cutia Therapeutics.

Provide EV/GP
for Cutia Therapeutics.

Provide EV/EBITDA
for Cutia Therapeutics.

Provide EV/EBIT
for Cutia Therapeutics.

Provide EV/OCF
for Cutia Therapeutics.

Provide EV/FCFF
for Cutia Therapeutics.

Provide EV/IC
for Cutia Therapeutics.

Show me price targets
for Cutia Therapeutics made by professional analysts.

What are the Revenue projections
for Cutia Therapeutics?

How accurate were the past Revenue estimates
for Cutia Therapeutics?

What are the Net Income projections
for Cutia Therapeutics?

How accurate were the past Net Income estimates
for Cutia Therapeutics?

What are the EPS projections
for Cutia Therapeutics?

How accurate were the past EPS estimates
for Cutia Therapeutics?

What are the EBIT projections
for Cutia Therapeutics?

How accurate were the past EBIT estimates
for Cutia Therapeutics?

Compare the revenue forecasts
for Cutia Therapeutics with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Cutia Therapeutics and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Cutia Therapeutics against its competitors.

Analyze the profit margins
(gross, operating, and net) of Cutia Therapeutics compared to its peers.

Compare the P/E ratios
of Cutia Therapeutics against its peers.

Discuss the investment returns and shareholder value creation
comparing Cutia Therapeutics with its peers.

Analyze the financial leverage
of Cutia Therapeutics compared to its main competitors.

Show all profitability ratios
for Cutia Therapeutics.

Provide ROE
for Cutia Therapeutics.

Provide ROA
for Cutia Therapeutics.

Provide ROIC
for Cutia Therapeutics.

Provide ROCE
for Cutia Therapeutics.

Provide Gross Margin
for Cutia Therapeutics.

Provide Operating Margin
for Cutia Therapeutics.

Provide Net Margin
for Cutia Therapeutics.

Provide FCF Margin
for Cutia Therapeutics.

Show all solvency ratios
for Cutia Therapeutics.

Provide D/E Ratio
for Cutia Therapeutics.

Provide D/A Ratio
for Cutia Therapeutics.

Provide Interest Coverage Ratio
for Cutia Therapeutics.

Provide Altman Z-Score Ratio
for Cutia Therapeutics.

Provide Quick Ratio
for Cutia Therapeutics.

Provide Current Ratio
for Cutia Therapeutics.

Provide Cash Ratio
for Cutia Therapeutics.

What is the historical Revenue growth
over the last 5 years for Cutia Therapeutics?

What is the historical Net Income growth
over the last 5 years for Cutia Therapeutics?

What is the current Free Cash Flow
of Cutia Therapeutics?

Discuss the annual earnings per share (EPS)
trend over the past five years for Cutia Therapeutics.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Revenue & Expenses Breakdown
Cutia Therapeutics

Balance Sheet Decomposition
Cutia Therapeutics

Current Assets 1.2B
Cash & Short-Term Investments 1B
Receivables 63.3m
Other Current Assets 107.7m
Non-Current Assets 297.7m
PP&E 227.6m
Intangibles 8.2m
Other Non-Current Assets 61.8m
Current Liabilities 237.8m
Accounts Payable 60m
Accrued Liabilities 28.6m
Short-Term Debt 130.3m
Other Current Liabilities 18.8m
Non-Current Liabilities 81.7m
Long-Term Debt 81.7m
Efficiency

Earnings Waterfall
Cutia Therapeutics

Revenue
198.9m CNY
Cost of Revenue
-98.8m CNY
Gross Profit
100.1m CNY
Operating Expenses
-635.6m CNY
Operating Income
-535.5m CNY
Other Expenses
11.2m CNY
Net Income
-524.3m CNY

Free Cash Flow Analysis
Cutia Therapeutics

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

Profitability Score
Profitability Due Diligence

Cutia Therapeutics's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Positive Gross Profit
Negative Operating Income
Negative Net Income
27/100
Profitability
Score

Cutia Therapeutics's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

Cutia Therapeutics's solvency score is 66/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Negative Net Debt
Low D/E
66/100
Solvency
Score

Cutia Therapeutics's solvency score is 66/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
Cutia Therapeutics

Wall Street analysts forecast Cutia Therapeutics stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Cutia Therapeutics is 15.2 HKD with a low forecast of 14.44 HKD and a high forecast of 15.96 HKD.

Lowest
Price Target
14.44 HKD
111% Upside
Average
Price Target
15.2 HKD
123% Upside
Highest
Price Target
15.96 HKD
134% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for Cutia Therapeutics?

Click here to dive deeper.

Dividends

Cutia Therapeutics
does not pay dividends
Shareholder Yield

Current shareholder yield for Cutia Therapeutics is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

See Also

Discover More
What is the Intrinsic Value of one Cutia Therapeutics stock?

The intrinsic value of one Cutia Therapeutics stock under the Base Case scenario is 11.5 HKD.

Is Cutia Therapeutics stock undervalued or overvalued?

Compared to the current market price of 6.83 HKD, Cutia Therapeutics is Undervalued by 41%.

Back to Top